Research Progress and Perspectives of Antibody-drug Conjugates Targeting Trophoblast Cell Surface Antigen-2 in Advanced Non-small Cell Lung Cancer
10.3779/j.issn.1009-3419.2024.101.25
- VernacularTitle:靶向TROP-2的抗体药物偶联物在晚期非小细胞肺癌中的研究进展及展望
- Author:
XU JINGYAN
1
;
LIU JIAQI
;
MEI SHIQI
;
ZHOU QING
Author Information
1. 510080 广州,广东省肺癌研究所,南方医科大学附属广东省人民医院(广东省医学科学院)
- Keywords:
Lung neoplasms;
Actionable genomic alterations;
Antibody-drug conjugates;
Trophoblast cell surface antigen-2;
Drug therapy
- From:
Chinese Journal of Lung Cancer
2024;27(10):763-776
- CountryChina
- Language:Chinese
-
Abstract:
Non-small cell lung cancer(NSCLC)remains a significant global health burden,and there is an urgent need for new treatment options.Trophoblast cell surface antigen-2(TROP-2),a target closely associated with NSCLC prog-nosis,has become a research hotspot in recent years.Notably,TROP-2-targeted antibody-drug conjugates(ADCs)have made groundbreaking advances in NSCLC therapy.Clinical studies have demonstrated that certain TROP-2 ADCs can significantly improve progression-free survival in previously treated patients with advanced or metastatic NSCLC,regardless of the presence of actionable genomic alterations.These agents have shown promising potential in both frontline and subsequent treatment settings.In terms of safety,while adverse effects affecting the hematologic,respiratory,and gastrointestinal systems are gener-ally manageable,close clinical monitoring and timely management are still required.In conclusion,TROP-2 ADCs hold great promise in the treatment of NSCLC.
